For mortality, adverse outcomes were associated with life support limitations, the need for ventilatory support (particularly IMV) 14 days after the initial remdesivir dose, lymphopenia, low albumin and hemoglobin levels, flu and/or coinfection, and cough. The gene discussed is ALB; the disease is lymphopenia.